trending Market Intelligence /marketintelligence/en/news-insights/trending/n7lrspro_56htxddnonz8a2 content esgSubNav
In This List

Regulus pauses clinical activities, reduces workforce to preserve capital

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Regulus pauses clinical activities, reduces workforce to preserve capital

Regulus Therapeutics Inc. said it paused certain clinical activities and will lay off about 60% of its workforce.

The San Diego-based biopharmaceutical company paused recruitment activities for its RG-012, its potential treatment for Alport syndrome. A phase 1 trial of RGLS4326, another kidney disease drug, was paused.

Regulus expects the restructuring to yield over $20 million in annualized savings, extending its cash runway into mid-2019.

"I am very disappointed that we need to take these drastic steps to preserve our capital," company President and CEO Jay Hagan said in a news release.

Regulus is in talks to potentially restructure a partnership with Paris-based Sanofi.